title: Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.
abstract: We recently reported that addition of epigenetic agents could overcome resistance of leukemic cells to monoclonal antibody-mediated anti-tumor effects in T-cell prolymphocytic leukemia. We also reported that epigenetic agents could induce expression of the CD30 gene, thus providing a therapeutic target for the antibody drug conjugate brentuximab vedotin. Here we discuss these findings and their generality to treatment of other hematologic and solid malignancies.
authors.affiliation: Sierra Epigenetics LLC, Granite Bay, CA. Electronic address: epner5@msn.com.
authors.forename: Elliot M
authors.initials: EM
authors.lastname: Epner
authors.affiliation: Department of Pathology, Windsor University, Cayon, St Kitts.
authors.forename: Bikramajit Singh
authors.initials: BS
authors.lastname: Saroya
authors.affiliation: Department of Microbiology and Immunology, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, PA.
authors.forename: Zainul S
authors.initials: ZS
authors.lastname: Hasanali
authors.affiliation: Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, VA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Loughran
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D019008:Drug Resistance, Neoplasm; D044127:Epigenesis, Genetic / Q000187:drug effects*; D019337:Hematologic Neoplasms / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin